By Spondylitis Association of America
Friday, July 27, 2018
The following is an announcement from SAA about a third party clinical trial. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
A phase 4 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate in a study evaluating the clinical difference between 300 mg and 150 mg of secukinumab.
The purpose of the trial, titled, “Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)” is to investigate the effectiveness, impact, and performance of different secukinumab doses by comparing the effects of 150 mg and 300 mg.
Study qualifications include:
More information can be found on the Clinical Trials website.
This study is sponsored by Novartis who has created an informational website for the study. You’ll find additional information, including qualification criteria and participating sites at http://www.asleap.com/.
You can also call (866) 244 - 9578, email firstname.lastname@example.org, or visit the clinical trials study locations page.
Learn more about participating in Clinical Studies
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.